Abstract
In 1966, Laron, Pertzelan, and Mannheimer (1) reported the clinical phenotype of GH deficiency combined with elevated serum levels of GH. Subsequent studies demonstrated that increased GH secretion in such patients was the consequence of GH insensitivity, typically resulting from abnormalities of the GH receptor (GH-R) gene (2).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone: a new inborn error of metabolism. Isr J Med Sci 1966;2:152–5.
Rosenfeld R, Rosenbloom AL, Guevara-Aguirre J. Growth hormone insensitivity due to growth hormone receptor deficiency. Endocr Rev 1994; 15:369–90.
Laron Z, Blum W, Chatelain P, et al. Classification of growth hormone insensitivity syndrome. J Pediatr 1993;122:241.
Guler HP, Zapf J, Froesch ER. Short-term metabolic effects and half-lives of intravenously administered insulinlike growth factor I in healthy adults. N Engl J Med 1987;317:137–40.
Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor-I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989;86:2868–72.
Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man: estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989;121:753–7.
Takano K, Hizuka N, Shizume K, Asakawa K, Fukuda I, Demura H. Repeated sc administration of recombinant human insulin-like growth factor-I (IGF-I) to human subjects for seven days. Growth Reg 1991;1:23–8.
Wilton P, Sietnicks A, Gunnarsson R, Berger L, Grahnen A. Pharmacokinetic profile of recombinant human insulin-like growth factor-I given subcutaneously in normal subjects. Acta Paediatr Scand (Suppl) 1991;377:111–4.
Zapf J, Hauri C, Waldvogel M, et al. Recombinant human insulin-like growth factor induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc Natl Acad Sci USA 1989;86:3813–7.
Clemmons DR, Thissen JP, Maes M, Ketelslegers JM, Underwood LE. Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or protein-deprived rats induces specific IGF-binding proteins in serum. Endocrinology 1989;125:2967–72.
Glasscock GF, Hein AN, Miller JA, Hintz RL, Rosenfeld RG. Effects of continuous infusion of insulin-like growth factor-I and II, alone and in combination with thyroxine or growth hormone, on the neonatal hypophysectomized rat. Endocrinology 1992;130:203–10.
Laron Z, Erster B, Klinger B, Anin S. Effect of acute administration of insulin-like growth factor-I in patients with Laron-type dwarfism. Lancet 1988;2:1170–2.
Laron Z, Klinger B, Jensen JT, Erster B. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol 1991;35:145–50.
Walker JL, Ginalska-Malinowska M, Romer TE, Pucilowska JB, Underwood LE. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med 1991;324:1483–8.
Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency (GHRD)/Laron syndrome. J Clin Endocrinol Metab 1993;77:273–80.
Laron Z, Anin S, Klipper-Auerbach Y, Klinger B. Effects of insulin-like growth factor-I on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992;339:1258–61.
Walker J, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth-I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992;121:641–6.
Wilton P (on behalf of the Kabi Pharmacia Study Group). Treatment with recombinant insulin-like growth factor-I of children with growth hormone receptor deficiency (Laron syndrome). Acta Paediatr Scand (Suppl) 1992; 282:137–41.
Savage MO, Wilton P, Ranke MB, et al. Therapeutic response to recombinant IGF-I in thirty-two patients with growth hormone insensitivity [Abstract 17]. Pediatr Res 1993;33:S5.
Guevara-Aguirre J, De la Torre W, Rosenbloom AL, Acosta M, Rosenfeld RG. Osteopenia in menstruating women with IGF-I deficiency due to growth hormone receptor deficiency [Abstract 1417]. Proc 73rd annu meet Endocr Soc 1991:385.
Guler HP, Zapf J, Schweiwiller E, Froesch ER. Recombinant human insulin-like growth factor-I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 1988;85:4889–93.
Cottam YH, Blair WT, Gallaher BW, et al. Body growth, carcass composition and endocrine changes in lambs chronically treated with recombinantly derived insulin-like growth factor-I. Endocrinology 1992;130:2924–30.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this paper
Cite this paper
Rosenfeld, R.G., Rosenbloom, A.L., Guevara-Aguirre, J. (1995). Use of Recombinant IGF-I in Syndromes of GH Insensitivity. In: Blackman, M.R., Roth, J., Harman, S.M., Shapiro, J.R. (eds) GHRH, GH, and IGF-I. Serono Symposia USA. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-0807-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-4612-0807-5_13
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-6908-3
Online ISBN: 978-1-4612-0807-5
eBook Packages: Springer Book Archive